Why $STML is UP 56% #BeforeBell @ $7.50 ?

Recently stock market analysts have updated their consensus ratings on shares of Stemline Therapeutics, Inc. (STML). The latest broker reports which are currently outstanding on Tuesday 19th January state 3 analysts have a rating of “strong buy”, 3 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

12/07/2015 – Stemline Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 19 price target on the stock.

05/13/2015 – Stemline Therapeutics, Inc. was downgraded to “hold” by analysts at Zacks.

04/27/2015 – H.C. Wainwright began new coverage on Stemline Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 38 price target on the stock.

04/22/2015 – Stemline Therapeutics, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 30 price target on the stock.

01/30/2015 – Stemline Therapeutics, Inc. had its “buy” rating reiterated by analysts at Aegis Capital. They now have a USD 55 price target on the stock.

01/26/2015 – Stemline Therapeutics, Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 50 price target on the stock.

01/23/2015 – Cowen began new coverage on Stemline Therapeutics, Inc. giving the company a “outperform” rating.

02/14/2014 – WBB Securities began new coverage on Stemline Therapeutics, Inc. giving the company a “sell” rating. They now have a USD 9 price target on the stock.

Stemline Therapeutics, Inc. has a 50 day moving average of 6.40 and a 200 day moving average of 9.05. The stock’s market capitalization is 85.14M, it has a 52-week low of 4.55 and a 52-week high of 17.40.

The share price of the company (STML) was down -3.95%, with a high of 4.99during the day and the volume of Stemline Therapeutics, Inc. shares traded was 72936.

Stemline Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company develops two clinical stage product candidates, SL-401 and SL-701, as well as a pipeline of preclinical candidates, SL-801 and SL-501. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R), present on CSCs and tumor bulk of a variety of hematologic cancers. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-801 is an oral small molecule reversible inhibitor of nuclear transport, targeting Exportin-1 (XPO1). SL-501 is a rationally designed IL-3R-targeted therapeutic. The Company’s activities include advancing two clinical stage programs, expanding and strengthening its property portfolio, developing drug discovery platform, identifying and acquiring additional product and technology rights and raising capital.

By: Sylvia Delisle | Risers and Fallers

Analyst Coverage Updates - Stemline Therapeutics, Inc. (STML)

Recently stock market analysts have updated their consensus ratings on shares of Stemline Therapeutics, Inc. (STML). The latest broker reports which are currently outstanding on Tuesday 19th January state 3 analysts have a rating of "strong buy", 3 analysts "buy", 0 analysts "neutral", 0 analysts "sell" and 0 analysts "strong sell".